Peringatan Keamanan

Patients experiencing an overdose may present with abdominal pain, agitation, palpitations, seizures, angina, hypertension, hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, nausea, dizziness, fatigue, malaise, insomnia.A230323,L32093,L32098 Discontinue treatment with terbutaline and initiate symptomatic and supportive therapy.L32093,L32098

Terbutaline

DB00871

small molecule approved

Deskripsi

Terbutaline was first synthesized in 1966A230333 and described in the literature in the late 1960s and early 1970s.A230328 It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.A230333,L32093,L32098

Terbutaline was granted FDA approval on 25 March 1974.L32088

Struktur Molekul 2D

Berat 225.2842
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) An oral dose of terbutaline has an elimination half life of 3.4 hours,[L32098] while a subcutaneous dose has an elimination half life of 2.9 hours.[L32093]
Volume Distribusi Terbutaline has a mean volume of distribution of 1.6 L/kg.[A229983]
Klirens (Clearance) The average clearance of terbutaline is 3.0 mL/min/kg.[A229983]

Absorpsi

A 0.5 mg subcutaneous dose of terbutaline reaches a mean Cmax of 9.6 ± ng/mL, with a median Tmax of 0.5 hours, and a mean AUC of 29.4 ± 14.2 h\*ng/mL.L32093 A 5 mg oral terbutaline tablet reaches a mean Cmax of 8.3 ± 3.9 ng/mL with a median Tmax of 2 hours, and a mean AUC of 54.6 ± 26.8 h\*ng/mL.L32098 A 5 mg oral terbutaline solution reaches a mean Cmax of 8.6 ± 3.6 ng/mL, with a median Tmax of 1.5 hours, and a mean AUC of 53.1 ± 23.5 h\*ng/mL.L32098 Oral terbutaline has an oral bioavailability of 14-15%.A229983

Metabolisme

Terbutaline is sulphated or glucuronidated prior to elimination.A229963,A229968,A229973,A230233

Rute Eliminasi

An oral dose of terbutaline is 40% eliminated in the urine after 72 hours.A229973 The major metabolite in the urine was the sulphate conjugated form of terbutaline.A229973 Parenteral doses of terbutaline are 90% eliminated in the urine, with approximately 2/3 as the unchanged parent drug.A229978 Less than 1% of a dose of terbutaline is eliminated in the feces.A229978

Interaksi Obat

1596 Data
Loxapine The therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine.
Valsartan Terbutaline may decrease the antihypertensive activities of Valsartan.
Ramipril Terbutaline may decrease the antihypertensive activities of Ramipril.
Remikiren Terbutaline may decrease the antihypertensive activities of Remikiren.
Olmesartan Terbutaline may decrease the antihypertensive activities of Olmesartan.
Minoxidil Terbutaline may decrease the antihypertensive activities of Minoxidil.
Trandolapril Terbutaline may decrease the antihypertensive activities of Trandolapril.
Lercanidipine Terbutaline may decrease the antihypertensive activities of Lercanidipine.
Benazepril Terbutaline may decrease the antihypertensive activities of Benazepril.
Bosentan Terbutaline may decrease the antihypertensive activities of Bosentan.
Enalapril Terbutaline may decrease the antihypertensive activities of Enalapril.
Candoxatril Terbutaline may decrease the antihypertensive activities of Candoxatril.
Nitroglycerin Terbutaline may decrease the antihypertensive activities of Nitroglycerin.
Metyrosine Terbutaline may decrease the antihypertensive activities of Metyrosine.
Cryptenamine Terbutaline may decrease the antihypertensive activities of Cryptenamine.
Candesartan cilexetil Terbutaline may decrease the antihypertensive activities of Candesartan cilexetil.
Eprosartan Terbutaline may decrease the antihypertensive activities of Eprosartan.
Quinapril Terbutaline may decrease the antihypertensive activities of Quinapril.
Telmisartan Terbutaline may decrease the antihypertensive activities of Telmisartan.
Irbesartan Terbutaline may decrease the antihypertensive activities of Irbesartan.
Deserpidine Terbutaline may decrease the antihypertensive activities of Deserpidine.
Captopril Terbutaline may decrease the antihypertensive activities of Captopril.
Cilazapril Terbutaline may decrease the antihypertensive activities of Cilazapril.
Saprisartan Terbutaline may decrease the antihypertensive activities of Saprisartan.
Spirapril Terbutaline may decrease the antihypertensive activities of Spirapril.
Debrisoquine Terbutaline may decrease the antihypertensive activities of Debrisoquine.
Sitaxentan Terbutaline may decrease the antihypertensive activities of Sitaxentan.
Ambrisentan Terbutaline may decrease the antihypertensive activities of Ambrisentan.
Diethylnorspermine Terbutaline may decrease the antihypertensive activities of Diethylnorspermine.
Pinacidil Terbutaline may decrease the antihypertensive activities of Pinacidil.
Temocapril Terbutaline may decrease the antihypertensive activities of Temocapril.
Riociguat Terbutaline may decrease the antihypertensive activities of Riociguat.
Aliskiren Terbutaline may decrease the antihypertensive activities of Aliskiren.
Manidipine Terbutaline may decrease the antihypertensive activities of Manidipine.
Rauwolfia serpentina root Terbutaline may decrease the antihypertensive activities of Rauwolfia serpentina root.
Selexipag Terbutaline may decrease the antihypertensive activities of Selexipag.
Angiotensin 1-7 Terbutaline may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Terbutaline may decrease the antihypertensive activities of Imidapril.
BQ-123 Terbutaline may decrease the antihypertensive activities of BQ-123.
Dihydralazine Terbutaline may decrease the antihypertensive activities of Dihydralazine.
Zofenopril Terbutaline may decrease the antihypertensive activities of Zofenopril.
Guanoxan Terbutaline may decrease the antihypertensive activities of Guanoxan.
Delapril Terbutaline may decrease the antihypertensive activities of Delapril.
Vincamine Terbutaline may decrease the antihypertensive activities of Vincamine.
Linsidomine Terbutaline may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Terbutaline may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Terbutaline may decrease the antihypertensive activities of Tolonidine.
Endralazine Terbutaline may decrease the antihypertensive activities of Endralazine.
Cadralazine Terbutaline may decrease the antihypertensive activities of Cadralazine.
Bietaserpine Terbutaline may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Terbutaline may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Terbutaline may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Terbutaline may decrease the antihypertensive activities of Guanoclor.
Candesartan Terbutaline may decrease the antihypertensive activities of Candesartan.
Dexniguldipine Terbutaline may decrease the antihypertensive activities of Dexniguldipine.
Tocopherylquinone Terbutaline may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Terbutaline may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Terbutaline may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Terbutaline may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Terbutaline may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Terbutaline may decrease the antihypertensive activities of Quinaprilat.
Amlodipine Terbutaline may decrease the antihypertensive activities of Amlodipine.
Levamlodipine Terbutaline may decrease the antihypertensive activities of Levamlodipine.
Azilsartan medoxomil Terbutaline may decrease the antihypertensive activities of Azilsartan medoxomil.
Diazoxide Terbutaline may decrease the antihypertensive activities of Diazoxide.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Terbutaline.
Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Terbutaline.
Bethanidine Terbutaline may decrease the antihypertensive activities of Bethanidine.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Terbutaline.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Terbutaline.
Clonidine Terbutaline may decrease the antihypertensive activities of Clonidine.
Guanabenz Terbutaline may decrease the antihypertensive activities of Guanabenz.
Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with Terbutaline.
Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Terbutaline.
Omapatrilat Terbutaline may decrease the antihypertensive activities of Omapatrilat.
Remifentanil The risk or severity of hypertension can be increased when Terbutaline is combined with Remifentanil.
Naratriptan The risk or severity of hypertension can be increased when Terbutaline is combined with Naratriptan.
Frovatriptan The risk or severity of hypertension can be increased when Terbutaline is combined with Frovatriptan.
Methoxyflurane The risk or severity of hypertension can be increased when Terbutaline is combined with Methoxyflurane.
Dutasteride The risk or severity of hypertension can be increased when Terbutaline is combined with Dutasteride.
Halothane The risk or severity of hypertension can be increased when Terbutaline is combined with Halothane.
Rescinnamine Terbutaline may decrease the antihypertensive activities of Rescinnamine.
Finasteride The risk or severity of hypertension can be increased when Terbutaline is combined with Finasteride.
Yohimbine The risk or severity of hypertension can be increased when Terbutaline is combined with Yohimbine.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when Terbutaline is combined with 4-Methoxyamphetamine.
Phendimetrazine The risk or severity of hypertension can be increased when Terbutaline is combined with Phendimetrazine.
Epicaptopril The risk or severity of hypertension can be increased when Terbutaline is combined with Epicaptopril.
Taxifolin The risk or severity of hypertension can be increased when Terbutaline is combined with Taxifolin.
1-benzylimidazole The risk or severity of hypertension can be increased when Terbutaline is combined with 1-benzylimidazole.
Flibanserin The risk or severity of hypertension can be increased when Terbutaline is combined with Flibanserin.
Rotigotine The risk or severity of hypertension can be increased when Terbutaline is combined with Rotigotine.
Amibegron The risk or severity of hypertension can be increased when Terbutaline is combined with Amibegron.
Naluzotan The risk or severity of hypertension can be increased when Terbutaline is combined with Naluzotan.
Cariprazine The risk or severity of hypertension can be increased when Terbutaline is combined with Cariprazine.
Mianserin The risk or severity of hypertension can be increased when Terbutaline is combined with Mianserin.
Solabegron The risk or severity of hypertension can be increased when Terbutaline is combined with Solabegron.
Esmirtazapine The risk or severity of hypertension can be increased when Terbutaline is combined with Esmirtazapine.
Vilazodone The risk or severity of hypertension can be increased when Terbutaline is combined with Vilazodone.
Nitrous oxide The risk or severity of hypertension can be increased when Terbutaline is combined with Nitrous oxide.
Xylometazoline The risk or severity of hypertension can be increased when Terbutaline is combined with Xylometazoline.

Target Protein

Beta-2 adrenergic receptor ADRB2
Beta-3 adrenergic receptor ADRB3
Beta-1 adrenergic receptor ADRB1

Referensi & Sumber

Synthesis reference: Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.
Artikel (PubMed)
  • PMID: 14610225
    Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10.
  • PMID: 1358833
    Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62.
  • PMID: 2062329
    Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92.
  • PMID: 22454899
    Davies DS, George CF, Blackwell E, Conolly ME, Dollery CT: Metabolism of terbutaline in man and dog. Br J Clin Pharmacol. 1974 Apr;1(2):129-36. doi: 10.1111/j.1365-2125.1974.tb00221.x.
  • PMID: -
    Nilsson HT, Persson K, Tegner K: The Metabolism of Terbutaline in Man Xenobiotica. 1972 Mar 16;2(4):363-373.
  • PMID: 6586478
    Ripe E, Hornblad Y, Tegner K: Oral administration of terbutaline in asthmatic patients. Eur J Respir Dis Suppl. 1984;134:171-9.
  • PMID: 6586491
    Tegner K, Nilsson HT, Persson CG, Persson K, Ryrfeldt A: Elimination pathways of terbutaline. Eur J Respir Dis Suppl. 1984;134:93-100.
  • PMID: 6586475
    Nyberg L: Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis Suppl. 1984;134:149-60.
Menampilkan 8 dari 13 artikel.
Textbook
  • ISBN: 978-0-12-386455-0
    Spiller H (2014). Terbutaline. In Encyclopedia of Toxicology (Third Edition) (3rd ed., pp. 484-485). Elsevier.

Contoh Produk & Brand

Produk: 47 • International brands: 8
Produk
  • Bricanyl Tab 2.5 mg
    Tablet • 2.5 mg • Oral • Canada • Approved
  • Bricanyl Tab 5 mg
    Tablet • 5 mg • Oral • Canada • Approved
  • Bricanyl Turbuhaler
    Powder • 0.5 mg / dose • Respiratory (inhalation) • Canada • Approved
  • Terbutaline Sulfate
    Tablet • 2.5 mg/1 • Oral • US • Generic • Approved
  • Terbutaline Sulfate
    Tablet • 2.5 mg/1 • Oral • US • Generic • Approved
  • Terbutaline Sulfate
    Tablet • 5 mg/1 • Oral • US • Generic • Approved
  • Terbutaline Sulfate
    Injection • 1 mg/1mL • Subcutaneous • US • Generic • Approved
  • Terbutaline Sulfate
    Injection • 1 mg/1mL • Subcutaneous • US • Generic • Approved
Menampilkan 8 dari 47 produk.
International Brands
  • Brethaire — Novartis
  • Brethine
  • Bricanyl — AstraZeneca
  • Bricardyl — Johnson
  • Bricasma — AstraZeneca
  • Bricasol — AstraZeneca
  • Dracanyl — AstraZeneca
  • Terbasmin — AstraZeneca

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul